目的　研究联苯苄唑的正常人体药物动力学 ,以对联苯苄唑的安全性作一评价。方法　采用GC MS单离子检测的方法测定联苯苄唑溶液剂和霜剂在 8名正常人体的血药浓度 ,并用 3P87软件估算了药物动力学参数。结果　溶液剂和霜剂的体内过程均符合二室开放模型 ,tmax分别为 2 .91和 5 .6 1h ,cmax分别为 713.46和 410 .70ng·mL-1。霜剂吸收、分布和清除较溶液剂慢 ,但曲线峰下面积没有显著性差别。结论　联苯苄唑是一个较安全的外用药物 ,建议临床上交替使用 ,以提高疗效 Objective To study the normal human pharmacokinetics of bifonazole in order to evaluate the safety of bifonazole. Methods The plasma concentrations of bifonazole solution and cream in eight normal human subjects were determined by GC MS single ion method. Pharmacokinetic parameters were estimated by 3P87 software. Results The in vivo process of both solutions and creams was in accordance with the two-compartment open model with tmax of 2.91 and 5.61 h, respectively, with cmax of 713.46 and 410 .70 ng · mL -1, respectively. Cream absorption, distribution and removal slower than the solution, but the area under the curve did not differ significantly. Conclusion Bifonazole is a safer topical drug, it is recommended to use clinically alternating to improve efficacy